Latest News

Grace Therapeutics Submits NDA for GTX-104 to Treat Aneurysmal Subarachnoid Hemorrhage
Grace Therapeutics Submits NDA for GTX-104 to Treat Aneurysmal Subarachnoid Hemorrhage

June 25th 2025

Grace Therapeutics submits NDA for GTx-104, a promising IV treatment for aSAH, aiming to revolutionize patient care and improve outcomes.

NeuroVoices: Stewart Tepper, MD, on Understanding Newly Approved STS101 for Acute Migraine
NeuroVoices: Stewart Tepper, MD, on Understanding Newly Approved STS101 for Acute Migraine

June 25th 2025

FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis
FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis

June 24th 2025

Bill Haney (Credit: Global Genes)
Patient Dosing Underway in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington Disease

June 24th 2025

Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine
Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine

June 24th 2025

Coverage of SLEEP 2025

Get direct access to interviews with experts, straight from the conference floor in Seattle, as well as the latest data and clinical news updates.

SLEEP 2025

Conference Coverage

View All
Souvik Sen, MD, MPH, FAHA
Insights on Migraine, Autonomic Dysfunction, and Stroke Risk from the ARIC Study: Souvik Sen, MD, MPH, FAHA

June 25th 2025

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD
Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD

June 24th 2025

Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine
Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine

June 24th 2025

Elizabeth W. Leroux, MD, FRCPC
Patients Voicing Key Needs for Migraine Care and Advocacy: Elizabeth W. Leroux, MD, FRCPC

June 24th 2025

Video Series
Video Interviews
Podcasts

Most Recent

© 2025 MJH Life Sciences

All rights reserved.